Due to the limited number of animals available for this study, these differences in the IgG titres reached significance only at week 28. A neonatal macaque study showed that passively transferred non-nAbs did not protect the animals against oral challenge with SIVmac251 indicating that ADCC is not a main mechanism in reducing infection [29]. This is in contrast to recently reported findings which indicate that ADCC or the interaction of FcR with the Fc-region of the Abs may contribute to the elimination of retroviral infections [8,30]. Furthermore, the data presented in the present Mouse monoclonal to CK1 study suggests that C activation is part of the humoral immune response. different vaccination groups. In contrast, the amount of the observed complement-mediated lysis did not correlate with the reduction of SIV titres. == Conclusion == The heterologous prime-boost strategy with replication-deficient viral vectors administered exclusively via the tonsils did not induce any neutralizing antibodies before challenge. However, after challenge, comparable SIV-specific humoral immune responses were observed in all vaccinated animals. Immunization with single cycle immunodeficiency viruses mounts humoral immune responses comparable to live-attenuated immunodeficiency virus vaccines. == Background == Beside cellular immune responses, humoral immunity is considered a key component in AIDS vaccine development. Already during early stages of viral infection, anti-envelope (env) antibodies (Abs) are thought to reduce viremia [1-3]. Their effector functions are still not completely defined. Some of such neutralizing antibodies (nAbs) may inhibit viral entry either by interfering with structures of the gp120/gp41 complex [4] or with env-epitopes Calcipotriol monohydrate that bind to chemokine receptors. Alternatively, they may cross-link virus particles and induce clearance of immune-complexed viruses by phagocytosis. Additionally, antibody dependent cellular cytotoxicity (ADCC) is thought to appear early during acute infection [5] and can also be detected at later stages of disease progression. ADCC has been studied in the SIV monkey model, was associated with the control of HIV in infected humans [6-8] and may contribute to a slower disease progression in long-term non-progressors [9]. A further arm of the humoral immune response is the complement system as an important mechanism of innate immune defence. Complement (C) has been shown to enhance the activity of nAbs [10]. In synergy to the binding of Abs to viruses, C3 deposition, opsonization and immune complex formation are Calcipotriol monohydrate suggested to contribute to Calcipotriol monohydrate reduced viral infection rates. There is evidence that C-mediated lysis contributes mainly at early stages of HIV-1 infection to viremia control Calcipotriol monohydrate [11-13]. A major focus of current research is the design of safe and efficient vaccines providing a high level of protection against HIV. A promising approach is the application of replication-deficient single-cycle immunodeficiency viruses (SCIV) [14,15]. Upon application, these viral constructs undergo only one single round of replication resulting in the production of non-infectious virus-like particlesin vivo. The induced immune response is thought to protect from challenge by clearing infected cells. A non-invasive application of live-attenuated SIV vaccines to the mucosa via the tonsils has been established. This approach induced protection against challenge with homologous SIV and SHIV, a SIV/HIV-1 hybridvirus containing HIV-1 envelope in the SIV backbone [16,17]. Although effective, the delivery of attenuated retroviruses is not feasible in humans due to safety concerns [18,19]. Thus, we adopted a heterologous prime-boost regimen through priming with SCIV and boosting with Adeno5 (Ad5)-SIV or SCIV. The vectors were either given systemically or exclusively mucosally. To elucidate the induction of immune responses upon vaccination, 12 rhesus macaques were primed with SCIV. Four of the animals received the immunizations via the tonsillar route and eight intravenously (iv) (Table1). The SCIVs used for priming were pseudotyped with the G protein of vesicular stomatitis virus (VSV-G) to favour and enhance expression of SIV-virus like particles in a broad spectrum of cells, including dendritic cells [20]. The four tonsillar and four of the iv immunized monkeys were boosted with two adenoviral vectors expressing SIV-gag-pol, and SIV env and Calcipotriol monohydrate rev, respectively. The remaining four iv SCIV immunized animals were boosted with SCIV pseudotyped with amphotropic murine leukemia virus envelope (SCIV [MLV]), since we previously observed rapid induction of VSV-G-nAbs after immunization with VSV-G pseudotyped SCIVs [15]. == Table 1. == Immunization regimen ainfectious units/ml bnumber of particles per construct cnumber of particles The results of the systemic spread of SCIV after oral immunization, as well as analyses concerning the cellular immune responses, immunohistochemical andin situhybridisation assays have been recently published by Stahl-Hennig et al. [21]. In the present study, we characterized the humoral immune response in immunized and challenged rhesus macaques and investigated the contribution of the induced neutralizing and non-neutralizing antibodies, C-deposition on the viral surface and C-mediated lysis with regard to the control of retroviral infection. == Results == == Viral load levels == At 20 weeks post infection (wpi) all vaccinated monkeys and the respective control animals were challenged with pathogenic SIVmac239 via the tonsils. Viremia peaked approximately 2.
